Clinical Trials Logo

Filter by:
NCT ID: NCT04803539 Recruiting - Breast Cancer Clinical Trials

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC

Artemis
Start date: April 1, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Circulating tumor DNA (ctDNA) has been demonstrated to be an effective prognostic marker in breast cancer. Various studies have shown that early TNBC breast cancer patients with positive ctDNA have high risk of cancer recurrence and worse prognosis. This study aimed to identify TNBC patients with positive ctDNA and initiate boost therapy in these high risk patients.

NCT ID: NCT04804956 Recruiting - Rectal Cancer Clinical Trials

Mesorectal Microbiome as a Prognostic Factor in Patients With Rectal Cancer

BIORECTUM
Start date: April 1, 2021
Phase:
Study type: Observational

The equilibrium of intestinal microorganisms is essential for health an imbalance has been associated with an increased risk in the development of different pathologies; including colorectal cancer. Rectal cancer is the third most common neoplasm worldwide and the complete excision of the mesorectum is a major prognostic factor. The identification of microorganisms in the adipose tissue that surrounds the small intestine in inflammatory diseases, together with bacterial alterations found in colonic mucosa and feces in patients with rectal cancer in comparison with healthy individuals indicates that microbiome alteration plays an essential role in pathogenesis. The mesorectal microbiome in rectal cancer patients stills unknown and given its importance in the prognostic of the disease the goal of this study is to identify microbial profiles that allow predicting rectal cancer patients with a poor prognosis.

NCT ID: NCT04807738 Recruiting - Multiple Sclerosis Clinical Trials

Virtual Reality in Physical Therapy in Multiple Sclerosis

VIREMS
Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The randomized controlled trial is aimed to study the efficacy of virtual reality (VR) and its impact on upper limb function and postural stability in people with mild to severe multiple sclerosis (pwMS). The conceptual idea is to compare two kinds of neuroproprioceptive "facilitation and inhibition" physical therapy, first in a real environment and second in virtual reality, in out-patient therapy that will be held in 15 hourly therapies, 2x a week in a period of two months. The efficacy will be assessed by a blinded independent clinical examiner using clinical examination and questionnaire survey before and in a week following the therapeutic intervention. The main focus is on upper limb gross and fine motor skills, trunk stability and stability, and sit to stand stability.

NCT ID: NCT04808856 Recruiting - Gout Clinical Trials

Treatment of Refractory Gout With ACTH or Methylprednisolone

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

To clarify the therapeutic effect and safety evaluation of ACTH in refractory gouty arthritis and special population, and to explore its mechanism of action.

NCT ID: NCT04809909 Recruiting - Low Back Pain Clinical Trials

Peripheral Stimulation of Acupuncture Points for Low Back Pain

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

For decades, chronic low back pain has been one of the major health complaints in Hong Kong. Without proper management, low back pain is associated with functional disability and decreased quality of life. However, currently, there is still no "gold standard" treatment for cure of the problem.

NCT ID: NCT04813523 Recruiting - Clinical trials for Neoadjuvant Chemotherapy

Pembrolizumab Plus Neoadjuvant Chemotherapy for Locally Advanced EGJ Adenocarcinoma

KEYSTONE-003
Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to observe and evaluate the efficacy and safety of pembrolizumab plus cisplatin and 5-fluorouracil (5-FU) followed Surgery for locally advanced adenocarcinoma of esophagogastric junction

NCT ID: NCT04815408 Recruiting - Ovarian Cancer Clinical Trials

PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer

Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to validate the efficacy and safety of anti-PD-1 in combination with neoadjuvant chemotherapy in women with advanced ovarian cancer.

NCT ID: NCT04816201 Recruiting - Electroacupuncture Clinical Trials

Electroacupuncture to Assist Ventilator Weaning in Severe Stroke

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy of electroacupuncture in assisting ventilator weaning in patients with severe stroke

NCT ID: NCT04817826 Recruiting - Gastric Cancer Clinical Trials

TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.

INFINITY
Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

INFINITY is a Phase II, multicentre, single-arm, multi-cohort trial aimed at evaluating the activity and safety of the combination of tremelimumab and durvalumab as neoadjuvant (Cohort 1) and definitive (Cohort 2) treatment for MSI-high gastric/gastroesophageal juction cancer patients eligible for radical surgery.

NCT ID: NCT04817956 Recruiting - Cancer Metastatic Clinical Trials

Improving Public Cancer Care by Implementing Precision Medicine in Norway

IMPRESS-N
Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

IMPRESS-Norway is a prospective, non-randomized clinical trial evaluating efficacy of commercially available, anti-cancer drugs prescribed for patients with advanced cancer diagnosed with potentially actionable alterations as revealed by molecular diagnostics. IMPRESS-Norway is a nation-wide study and all hospitals with an oncology and / or hematology department will be invited to participate in the study. The study will use a combined umbrella and basket design and a Simon two-stage model of expanding cohorts to follow up potentially effective combinations of biomarker and drug on specific indications. Sampling of biological material will be performed at presentation, during treatment and upon progression. Additional biomarker and translational analyses including whole genome sequencing (WGS) on tumour material and liquid biopsies, identifying mechanisms underlying drug sensitivity versus resistance will be performed.